自体DC-CIK细胞联合化疗治疗晚期非小细胞肺癌的临床观察  

Effect of antilogous cytokine induced killer cells and dendrite cells combined with chemotherapy on advanced non-small cell lung cancer patients

作　　者：王美清[1] 彭大为[1] 程小珍[1] 何立香[1] 谢宗宙[1] 朱燕兴[1] 

机构地区：[1]海口市人民医院肿瘤科,海南海口570208

出　　处：《中国热带医学》2012年第6期719-721,共3页China Tropical Medicine

摘　　要：目的观察自体DC-CIK细胞联合化疗治疗晚期非小细胞肺癌的疗效。方法62例确诊为肺癌的患者随机分为两组,A组31例(自体DC-CIK联合NP),B组31例(方案单用NP方案化疗),观察治疗前后的临床疗效及免疫学指标。结果 A组与B组比较,其有效率为(29.03%vs.19.35%),疾病控制率为(74.19%vs.51.60%)(P值分别为0.131、0.031),A组患者CD3+、CD4+细胞的百分比含量较治疗前明显提高,差异有统计学意义(P<0.05)。结论自体DC-CIK细胞联合化疗治疗晚期肺癌患者有控制肿瘤,改善生活质量及增强免疫功能的趋势。Objective To observe the clinical effects of autologous cytokine induced killer cells（CIK）and dendritic cells（DC）combined with chemotherapy on advanced non-small cell lung cancer（NSCLC）patients. Methods The 62 non-small lung cancere patients were randomly divided into group A comprised of 31 cases（DC-CIK＋NP chemotherapy group）and group B comprised of 31 cases（NP chemotherapy group）,by comparing the two groups of patients with lung cancer before and after treatment of clinical curative effect and T lymphocyte subtypes in peripheral blood. Results The effective rate in group A and group B were 29.03% and 19.35%,the response rate were 29.03%and 19.35%,and the disease control rate were 74.19% and.51.60%（P=0.131,P=0.031）.The levels of CD3＋and CD4＋in the group A increasd after treatment,which showed significant statistical difference. Conclusion The use of autologus DC-CIK combined with chemotherapy for treatment advanced NSCLC has advantages of inhibiting the growth of tumor,enhancing immune function and improving the quality of life.

关 键 词：肺癌 细胞免疫 DC-CIK 

分 类 号：R734.2[医药卫生—肿瘤]